ABUS / Arbutus Biopharma Corporation - SEC-Einreichungen, Jahresbericht, Proxy Statement

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 26, 2026 Arbutus Biopharma Co

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 26, 2026 Arbutus Biopharma Corporation (Exact name of registrant as specified in its charter) British Columbia, Canada 001-34949 98-0597776 (State or other jurisdiction of incorpo

ARBUTUS BIOPHARMA CORPORATION 2026 OMNIBUS SHARE AND INCENTIVE PLAN 1. PURPOSE The Plan is intended to (a) provide eligible persons with an incentive to contribute to the success of the Company and to operate and manage the Company’s business in a ma

arbutus2026omnibussharea ARBUTUS BIOPHARMA CORPORATION 2026 OMNIBUS SHARE AND INCENTIVE PLAN 1.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 13, 2026 Arbutus Biopharma Co

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 13, 2026 Arbutus Biopharma Corporation (Exact name of registrant as specified in its charter) British Columbia, Canada 001-34949 98-0597776 (State or Other Jurisdiction of Incorpo

Arbutus Reports First Quarter 2026 Financial Results and Provides Corporate Update Q1 total revenue of $179.1M includes estimated license revenue from Genevant related to litigation settlement with Moderna Strong financial position with cash, cash eq

EXHIBIT 99.1 Arbutus Reports First Quarter 2026 Financial Results and Provides Corporate Update Q1 total revenue of $179.1M includes estimated license revenue from Genevant related to litigation settlement with Moderna Strong financial position with cash, cash equivalents and marketable securities of $95.2M as of March 31, 2026 FDA granted Fast Track designation to imdusiran, which has the potenti

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2026 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period from to Commission File Number: 001-34949 ARBUTUS BIOPHARMA CO

Arbutus Receives U.S. FDA Fast Track Designation for Imdusiran for the Treatment of Chronic Hepatitis B Fast Track designation has the potential to facilitate development and accelerate FDA review of imdusiran

EXHIBIT 99.1 Arbutus Receives U.S. FDA Fast Track Designation for Imdusiran for the Treatment of Chronic Hepatitis B Fast Track designation has the potential to facilitate development and accelerate FDA review of imdusiran WARMINSTER, Pa., April 15, 2026 (GLOBE NEWSWIRE) - Arbutus Biopharma Corporation (Nasdaq: ABUS) (“Arbutus” or the “Company”), a clinical-stage biopharmaceutical company focused

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 14, 2026 Arbutus Biopharma

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 14, 2026 Arbutus Biopharma Corporation (Exact name of registrant as specified in its charter) British Columbia, Canada 001-34949 98-0597776 (State or Other Jurisdiction of Incor

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934         Filed by the Registrant ☒     Filed by a Party other than the Registrant  ☐         Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ D

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934         Filed by the Registrant ☒     Filed by a Party other than the Registrant  ☐         Check the appropriate box:  ☐ Preliminary Proxy Statement  ☐ Confidential, for Use of the Commission Only (as permitted by R

Arbutus Biopharma Corporation List of Subsidiaries Name Jurisdiction Arbutus Biopharma Inc. Delaware, United States of America

Exhibit 21.1 Arbutus Biopharma Corporation List of Subsidiaries Name Jurisdiction Arbutus Biopharma Inc. Delaware, United States of America

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended December 31, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period from to Commission File Number: 001-34949 Arbutus Biopharma Corpora

INDEMNITY AGREEMENT

Exhibit 10.1 INDEMNITY AGREEMENT THIS AGREEMENT has been entered into as of the day of , 20 BETWEEN: ARBUTUS BIOPHARMA CORPORATION, a company duly incorporated under the laws of the Province of British Columbia, and having an office at 701 Veterans Circle, Warminster, PA 18974 (the “Indemnitor”) AND: [insert name], with an address c/o 701 Veterans Circle, Warminster, PA 18974 USA (the “Indemnitee”

EXECUTION COPY 1 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY “[***]”, HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL SETTLEMENT AGREEMENT This

redactedsettlementagreem EXECUTION COPY 1 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY “[***]”, HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL SETTLEMENT AGREEMENT This Settlement Agreement (“Agreement”) is entered into as of March 3, 2026 (the “Effective Date”) by and between, on the one hand, Genevant Sciences GmbH ( “Genevant”), a limited liability company organized under the laws of Switzerland having a principal place of business at Viaduktstrasse 8, 4051 Basel, Switzerland, and Arbutus Biopharma Corp.

DESCRIPTION OF THE REGISTRANT’S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934

Exhibit 4.1 DESCRIPTION OF THE REGISTRANT’S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 As of the date of the Annual Report on Form 10-K of which this exhibit forms a part, the only class of securities of Arbutus Biopharma Corporation (“we,” “us” and “our”) registered under Section 12 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), i

Insider Trading Policy Amended and Restated on September 25, 2025 Insider Trading Policy Amended and Restated by the Arbutus Board on September 25, 2025 2 of 11 During the course of your relationship as a director, officer or employee of Arbutus Biop

ex19insidertradingpolicy Insider Trading Policy Amended and Restated on September 25, 2025 Insider Trading Policy Amended and Restated by the Arbutus Board on September 25, 2025 2 of 11 During the course of your relationship as a director, officer or employee of Arbutus Biopharma Corporation (the “Company”), you may receive material information that is not yet publicly available about the Company or about publicly-traded companies with which the Company has business dealings.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 23, 2026 Arbutus Biopharma

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 23, 2026 Arbutus Biopharma Corporation (Exact name of registrant as specified in its charter) British Columbia, Canada 001-34949 98-0597776 (State or Other Jurisdiction of Incor

Arbutus Reports Fourth Quarter and Year End 2025 Financial Results and Provides Corporate Update Strong financial position with cash, cash equivalents and marketable securities of $91.5M as of December 2025 $2.25B Moderna global settlement for infrin

EXHIBIT 99.1 Arbutus Reports Fourth Quarter and Year End 2025 Financial Results and Provides Corporate Update Strong financial position with cash, cash equivalents and marketable securities of $91.5M as of December 2025 $2.25B Moderna global settlement for infringement of lipid nanoparticle (LNP) delivery technology represents significant outcome for Arbutus and Genevant Two additional patients fr

Genevant Sciences and Arbutus Biopharma Announce $2.25 Billion Global Settlement With Moderna

EXHIBIT 99.1 Genevant Sciences and Arbutus Biopharma Announce $2.25 Billion Global Settlement With Moderna Moderna to pay Genevant and Arbutus $950 million upfront and an additional $1.3 billion contingent upon a favorable resolution of Moderna’s Section 1498 appeal If the $1.3 billion payment is realized, this settlement will be the largest disclosed patent settlement paid in the pharmaceutical i

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 3, 2026 Arbutus Biopharma C

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 3, 2026 Arbutus Biopharma Corporation (Exact name of registrant as specified in its charter) British Columbia, Canada 001-34949 98-0597776 (State or Other Jurisdiction of Incorp

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 17, 2026 Arbutus Biophar

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 17, 2026 Arbutus Biopharma Corporation (Exact name of registrant as specified in its charter) British Columbia, Canada 001-34949 98-0597776 (State or other jurisdiction of in

Case No. 1:22 - cv - 00252 - JDW MEMORANDUM Not every defense presents a triable issue . Defenses, like affirmative claims, can fail for a lack of evidence . Or they can fail because parties in patent cases only get to litigate an obviousness issue o

Exhibit 99.1 Case No. 1:22 - cv - 00252 - JDW MEMORANDUM Not every defense presents a triable issue . Defenses, like affirmative claims, can fail for a lack of evidence . Or they can fail because parties in patent cases only get to litigate an obviousness issue once, either in court or in IPR proceedings . But when a defendant offers admissible evidence, including an expert opinion, that creates a

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 2, 2026 Arbutus Biopharm

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 2, 2026 Arbutus Biopharma Corporation (Exact name of registrant as specified in its charter) British Columbia, Canada 001-34949 98-0597776 (State or other jurisdiction of inc

Case No. 1:22 - cv - 00252 - JDW MEMORANDUM In Star Trek, members of Starfleet must observe the Prime Directive, even as they jump into or come out of warp speed . In this case, Arbutus Biopharma Corp . and Genevant Sciences GmbH (collectively, “Arbu

Exhibit 99.1 Case No. 1:22 - cv - 00252 - JDW MEMORANDUM In Star Trek, members of Starfleet must observe the Prime Directive, even as they jump into or come out of warp speed . In this case, Arbutus Biopharma Corp . and Genevant Sciences GmbH (collectively, “Arbutus”) claim that during the U . S . Government’s own Operation Warp Speed to find a vaccine for Covid - 19 , Moderna Inc . and ModernaTX,

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 15, 2026 Arbutus Biopharm

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 15, 2026 Arbutus Biopharma Corporation (Exact name of registrant as specified in its charter) British Columbia, Canada 001-34949 98-0597776 (State or other jurisdiction of inc

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 11, 2025 Arbutus Biophar

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 11, 2025 Arbutus Biopharma Corporation (Exact name of registrant as specified in its charter) British Columbia, Canada 001-34949 98-0597776 (State or other jurisdiction of in

1 Genevant & Arbutus LNP Litigation Lindsay Androski Special Counsel, Genevant CEO, Arbutus Matt Gline CEO, Roivant For investor audiences only Forward - Looking Statements This presentation includes forward - looking statements that are subject to s

Exhibit 99.1 1 Genevant & Arbutus LNP Litigation Lindsay Androski Special Counsel, Genevant CEO, Arbutus Matt Gline CEO, Roivant For investor audiences only Forward - Looking Statements This presentation includes forward - looking statements that are subject to substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statement

Press release dated November 13, 2025

EXHIBIT 99.1 Arbutus Reports Third Quarter 2025 Financial Results and Provides Corporate Update Strong financial position with cash, cash equivalents and marketable securities of $93.7M Moderna litigation U.S. trial scheduled for March 2026; Favorable claim construction ruling in Pfizer-BioNTech litigation issued in September 2025 Additional analysis of imdusiran (AB-729) clinical data shows: - 46

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 13, 2025 Arbutus Biophar

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 13, 2025 Arbutus Biopharma Corporation (Exact name of registrant as specified in its charter) British Columbia, Canada 001-34949 98-0597776 (State or Other Jurisdiction of In

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period from to Commission File Number: 001-34949 ARBUTUS BIOPHARM

Corporate Presentation dated November 13, 2025

Exhibit 99.2 NASDAQ: ABUS ARBUTUSBIO.COM ©2025 ARBUTUS BIOPHARMA, INC . Corporate Presentation November 13, 2025 ©2025 ARBUTUS BIOPHARMA, INC . Forward - Looking Statements This presentation contains forward - looking statements within the meaning of the U . S . Private Securities Litigation Reform Act of 1995 and Canadian securities laws . All statements that are not historical facts are hereby i

Arbutus Announces Four Abstracts Accepted for Presentation at AASLD - The Liver Meeting® 2025 Multiple abstracts accepted featuring imdusiran clinical data – highlighting progress toward a potential functional cure for chronic hepatitis B virus AB-10

EXHIBIT 99.1 Arbutus Announces Four Abstracts Accepted for Presentation at AASLD - The Liver Meeting® 2025 Multiple abstracts accepted featuring imdusiran clinical data – highlighting progress toward a potential functional cure for chronic hepatitis B virus AB-101 clinical data abstract recognized as a Poster of Distinction WARMINSTER, Pa., Oct. 07, 2025 (GLOBE NEWSWIRE) - Arbutus Biopharma Corpor

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 7, 2025 Arbutus Biopharma

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 7, 2025 Arbutus Biopharma Corporation (Exact name of registrant as specified in its charter) British Columbia, Canada 001-34949 98-0597776 (State or Other Jurisdiction of Inco

UNITED STATES DISTRICT COURT DISTRICT OF NEW JERSEY

Exhibit 99.1 Case 3:23-cv-01876-ZNQ-TJB Document 247 Filed 09/09/25 Page 1 of 1 PageID: 6979 UNITED STATES DISTRICT COURT DISTRICT OF NEW JERSEY ARBUTUS PHARMA CORP., et al., Plaintiffs, Civil Action No. 3:23-cv-1876-ZNQ-TJB v. CLAIM CONSTRUCTION ORDER PFIZER, INC., et al., Defendants. QURAISHI, District Judge For the reasons set forth in the accompanying Opinion, the Court hereby construes the pa

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 9, 2025 Arbutus Biophar

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 9, 2025 Arbutus Biopharma Corporation (Exact name of registrant as specified in its charter) British Columbia, Canada 001-34949 98-0597776 (State or other jurisdiction of in

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period from to Commission File Number: 001-34949 ARBUTUS BIOPHARMA COR

Arbutus Reports Second Quarter 2025 Financial Results and Provides Corporate Update Q2 total revenue of $10.7M includes previously-deferred revenue following reacquisition of Greater China rights to imdusiran Dr. Roger Sawhney joins the Arbutus Board

EXHIBIT 99.1 Arbutus Reports Second Quarter 2025 Financial Results and Provides Corporate Update Q2 total revenue of $10.7M includes previously-deferred revenue following reacquisition of Greater China rights to imdusiran Dr. Roger Sawhney joins the Arbutus Board of Directors following resignation of Anuj Hasija Dr. Harry Janssen joins the Arbutus Scientific Advisory Board Strong financial positio

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 4, 2025 Arbutus Biopharma

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 4, 2025 Arbutus Biopharma Corporation (Exact name of registrant as specified in its charter) British Columbia, Canada 001-34949 98-0597776 (State or Other Jurisdiction of Incor

Termination Agreement, dated June 20, 2025, by and between Arbutus Biopharma Corporation and Qilu Pharmaceutical Co., Ltd.

EdgarFiling EXHIBIT 10.1 TERMINATION AGREEMENT This TERMINATION AGREEMENT (this “Termination Agreement”) is entered into as of as of the 20th day of June, 2025 (the “Termination Agreement Effective Date”), by and among Arbutus Biopharma Corporation, a British Columbia corporation (“Arbutus”), having a place of business at 701 Veterans Circle, Warminster, PA 18974, USA, and Qilu Pharmaceutical Co.,

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 20, 2025 Arbutus Biopharma C

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 20, 2025 Arbutus Biopharma Corporation (Exact name of registrant as specified in its charter) British Columbia, Canada 001-34949 98-0597776 (State or Other Jurisdiction of Incorp

Arbutus Reacquires Greater China Rights to Imdusiran and Announces Scientific Advisory Board with Late-Stage Clinical Focus Qilu Pharmaceutical and Arbutus mutually agree to conclude strategic partnership for imdusiran in Greater China Drs. Jordan Fe

EXHIBIT 99.1 Arbutus Reacquires Greater China Rights to Imdusiran and Announces Scientific Advisory Board with Late-Stage Clinical Focus Qilu Pharmaceutical and Arbutus mutually agree to conclude strategic partnership for imdusiran in Greater China Drs. Jordan Feld, Ed Gane, Anna Lok, Mark Sulkowski and Man-Fung Yuen join Arbutus Scientific Advisory Board WARMINSTER, Pa., June 25, 2025 (GLOBE NEWS

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 21, 2025 Arbutus Biopharma Co

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 21, 2025 Arbutus Biopharma Corporation (Exact name of registrant as specified in its charter) British Columbia, Canada 001-34949 98-0597776 (State or other jurisdiction of incorpo

Separation Agreement and General Release, dated effective April 1, 2025, by and between Arbutus Biopharma, Inc. and Karen Sims.

EXHIBIT 10.6 169892628.1 March 25, 2025 Karen Sims XXXXX XXXXX RE: Separation Agreement and General Release Dear Karen, Your employment with Arbutus Biopharma, Inc. (the “Company”) terminated effective March 25, 2025 (the “Separation Date”). This Separation Agreement and General Release (this “Agreement”) sets forth the terms and conditions under which the Company is offering you additional pay an

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 14, 2025 Arbutus Biopharma Co

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 14, 2025 Arbutus Biopharma Corporation (Exact name of registrant as specified in its charter) British Columbia, Canada 001-34949 98-0597776 (State or Other Jurisdiction of Incorpo

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period from to Commission File Number: 001-34949 ARBUTUS BIOPHARMA CO

Separation Agreement and General Release, dated effective April 2, 2025, by and between Arbutus Biopharma, Inc. and David Hastings.

EXHIBIT 10.7 March 27, 2025 David Hastings XXXXX XXXXX RE: Separation Agreement and General Release Dear Dave, In accordance with Section 4(f) of your Executive Employment Agreement with the Company, dated as of June 11, 2018 (as amended, your “Existing Employment Agreement”), the Board has approved termination of your employment with Arbutus Biopharma, Inc. (the “Company”) effective at 11:59pm on

Arbutus Reports First Quarter 2025 Financial Results and Provides Corporate Update Imdusiran combination therapy has functionally cured 8 patients with chronic hepatitis B (cHBV) to date, including 2 patients who received no interferon AB-101, oral s

EXHIBIT 99.1 Arbutus Reports First Quarter 2025 Financial Results and Provides Corporate Update Imdusiran combination therapy has functionally cured 8 patients with chronic hepatitis B (cHBV) to date, including 2 patients who received no interferon AB-101, oral small-molecule PD-L1 inhibitor, shown generally safe and well-tolerated with evidence of high receptor occupancy in Phase 1a/1b Andrew J.

Executive Employment Agreement, dated February 25, 2025, by and between Arbutus Biopharma, Inc. and Lindsay Androski.

#94951935v1 EXHIBIT 10.1 EXECUTIVE EMPLOYMENT AGREEMENT THIS EXECUTIVE EMPLOYMENT AGREEMENT (together with all exhibits hereto, this “Agreement”) is hereby entered into as of February 25, 2025 (the “Effective Date”), by and between Arbutus Biopharma, Inc. (the “Company”), and Lindsay Androski (“Executive”) (hereinafter collectively referred to as the “Parties”). RECITALS WHEREAS, the Company desir

Separation Agreement and General Release, dated effective March 25, 2025, by and between Arbutus Biopharma, Inc. and Michael J. McElhaugh.

EXHIBIT 10.4 March 4, 2025 Michael J. McElhaugh RE: Separation Agreement and General Release Dear Michael, Your employment with Arbutus Biopharma, Inc. (the “Company”) terminated effective February 24, 2025 (the “Separation Date”). This Separation Agreement and General Release (this “Agreement”) sets forth the terms and conditions under which the Company is offering you additional pay and benefits

Consulting Agreement, dated March 28, 2025, by and between Arbutus Biopharma, Inc. and Karen Sims.

ex105-karensimsconsultin CONFIDENTIAL Page 1 OF 18 #100059892v4 EXHIBIT 10.5 CONSULTING AGREEMENT THIS CONSULTING AGREEMENT (as amended, restated, amended and restated, supplemented or otherwise modified from time to time, the “Agreement”) is made and entered into as of the date of last signature below (the “Effective Date”), by and between Arbutus Biopharma, Inc. (the “Company”), a Delaware corpo

Executive Employment Agreement, dated March 25, 2025, by and between Arbutus Biopharma, Inc. and Tuan Nguyen.

ex103-tuannguyenemployme EXHIBIT 10.3 EXECUTIVE EMPLOYMENT AGREEMENT THIS EXECUTIVE EMPLOYMENT AGREEMENT (together with all exhibits hereto, this “Agreement”) is hereby entered into as of March 25, 2025 (the “Effective Date”), by and between Arbutus Biopharma, Inc. (the “Company”), and Tuan Nguyen (“Executive”) (hereinafter collectively referred to as the “Parties”). RECITALS WHEREAS, the Company

Arbutus Presents Clinical Trial Data from its Two HBV Assets, Imdusiran and AB-101, at the European Association for the Study of the Liver (EASL) Congress 2025 Data highlighted in late-breaker poster presentation shows that imdusiran achieves functio

EXHIBIT 99.1 Arbutus Presents Clinical Trial Data from its Two HBV Assets, Imdusiran and AB-101, at the European Association for the Study of the Liver (EASL) Congress 2025 Data highlighted in late-breaker poster presentation shows that imdusiran achieves functional cure in chronic hepatitis B (cHBV) patients when combined with VTP-300 and low dose nivolumab In a Phase 1a/1b clinical trial, AB-101

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 7, 2025 Arbutus Biopharma Cor

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 7, 2025 Arbutus Biopharma Corporation (Exact name of registrant as specified in its charter) British Columbia, Canada 001-34949 98-0597776 (State or Other Jurisdiction of Incorpor

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 23, 2025 Arbutus Biopharma

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 23, 2025 Arbutus Biopharma Corporation (Exact name of registrant as specified in its charter) British Columbia, Canada 001-34949 98-0597776 (State or Other Jurisdiction of Incor

Arbutus to Present Imdusiran and AB-101 Data at EASL Congress 2025 Five abstracts accepted for poster presentations

EXHIBIT 99.1 Arbutus to Present Imdusiran and AB-101 Data at EASL Congress 2025 Five abstracts accepted for poster presentations WARMINSTER, Pa., April 23, 2025 (GLOBE NEWSWIRE) - Arbutus Biopharma Corporation (Nasdaq: ABUS) (“Arbutus” or the “Company”), a clinical-stage biopharmaceutical company focused on infectious disease, today announced that five abstracts, including one late-breaker, have b

144

144 0001635326 XXXXXXXX LIVE 0001447028 Arbutus Biopharma Corp 001-34949 701 VETERANS CIRCLE WARMINSTER PA 18974 604-419-3200 McElhaugh Michael J.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant  ☐ Check the appropriate box:  ☐ Preliminary Proxy Statement  ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy St

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934         Filed by the Registrant ☒     Filed by a Party other than the Registrant  ☐         Check the appropriate box:  ☐ Preliminary Proxy Statement  ☐ Confidential, for Use of the Commission Only (as permitted by R

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 28, 2025 Arbutus Biopharma Corporation (Exact name of registrant as specified in its charter) British Columbia, Canada 001-34949 98-0597776 (State or other jurisdiction of incor

Arbutus Reports Fourth Quarter and Year End 2024 Financial Results and Provides Corporate Update Claim construction hearing for Pfizer/BioNTech mRNA-LNP vaccine litigation occurred in December 2024; outcome pending Jury trial in Moderna U.S. mRNA-LNP

EXHIBIT 99.1 Arbutus Reports Fourth Quarter and Year End 2024 Financial Results and Provides Corporate Update Claim construction hearing for Pfizer/BioNTech mRNA-LNP vaccine litigation occurred in December 2024; outcome pending Jury trial in Moderna U.S. mRNA-LNP vaccine litigation scheduled for September 2025 Reviewing pipeline and development plans for HBV programs Continued focus on efficient d

Non-Disturbance and Attornment Agreement by and among, the Company, Univest Bank and Trust Co., and Veterans Circle Group, LLC dated December 12, 2023 (incorporated herein by reference to Exhibit 10.16 to the Registrant’s Annual Report on Form 10-K for the year ended December 31, 2023, filed with the SEC on March 5, 2024).

Exhibit 10.16 PREPARED BY AND RECORD AND RETURN TO: Christopher W. Rosenbleeth, Esquire Stradley Ronon Stevens & Young, LLP 2600 One Commerce Square Philadelphia, PA 19103 Location: 701 Veterans Circle Municipality: Warminster Township County: Bucks State: Pennsylvania SUBORDINATION, NON-DISTURBANCE AND ATTORNMENT AGREEMENT THIS SUBORDINATION, NON-DISTURBANCE AND ATTORNMENT AGREEMENT (this “Agreem

Insider Trading Policy

Insider Trading Policy Amended and Restated by the Arbutus Board on December 10, 2020 Insider Trading Policy Approved by the Arbutus Board on December 10, 2020 2 of 10 During the course of your relationship as a director, officer or employee of Arbutus Biopharma Corporation (the “Company”), you may receive material information that is not yet publicly available about the Company or about publicly-traded companies with which the Company has business dealings.

Arbutus Biopharma Corporation Incentive Compensation Recovery Policy (incorporated herein by reference to Exhibit 97 to the Registrant’s Annual Report on Form 10-K for the year ended December 31, 2023, filed with the SEC on March 5, 2024).

Exhibit 97 Arbutus Biopharma Corporation Incentive Compensation Recovery Policy Adopted by the Board of Directors (the “Board”) of Arbutus Biopharma Corporation (the “Company”) on October 18, 2023 The Company is committed to conducting business in accordance with the highest ethical and legal standards, and the Board believes that a culture that emphasizes integrity and accountability is in the best interests of the Company and its shareholders and essential to the Company’s success.

Form of Arbutus Biopharma Corporation Indemnity Agreement.

Exhibit 10.1 INDEMNITY AGREEMENT THIS AGREEMENT has been entered into as of the day of , 20 BETWEEN: ARBUTUS BIOPHARMA CORPORATION, a company duly incorporated under the laws of the Province of British Columbia, and having an office at 701 Veterans Circle, Warminster, PA 18974 (the “Indemnitor”) AND: [insert name], with an address c/o 701 Veterans Circle, Warminster, PA 18974 USA (the “Indemnitee”

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 27, 2025 Arbutus Biopharma Corporation (Exact name of registrant as specified in its charter) British Columbia, Canada 001-34949 98-0597776 (State or Other Jurisdiction of Incor

Description of Securities Registered Pursuant to Section 12 of the Securities Exchange Act of 1934.

lExhibit 4.1 DESCRIPTION OF THE REGISTRANT’S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 As of the date of the Annual Report on Form 10-K of which this exhibit forms a part, the only class of securities of Arbutus Biopharma Corporation (“we,” “us” and “our”) registered under Section 12 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”),

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended December 31, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period from to Commission File Number: 001-34949 Arbutus Biopharma Corpora

List of Subsidiaries.

Exhibit 21.1 Arbutus Biopharma Corporation List of Subsidiaries Name Jurisdiction Arbutus Biopharma Inc. Delaware, United States of America

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 3, 2025 Arbutus Biopharma C

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 3, 2025 Arbutus Biopharma Corporation (Exact name of registrant as specified in its charter) British Columbia, Canada 001-34949 98-0597776 (State or Other Jurisdiction of Incorp

Agreement, dated March 2, 2025, by and between Arbutus Biopharma Corporation and Genevant Sciences GmbH

Exhibit 10.1 AGREEMENT This Agreement (this “Agreement”) is made as of March 2, 2025 (the “Effective Date”), by and between Arbutus Biopharma Corp., a British Columbia corporation (“Arbutus”), and Genevant Sciences GmbH, a limited liability company organized and existing under the laws of Switzerland (“Genevant”). Arbutus and Genevant may be referred to herein individually as a “Party” and togethe

Genevant Sciences and Arbutus Biopharma Initiate International Patent Infringement Enforcement Actions Against Moderna

EXHIBIT 99.1 Genevant Sciences and Arbutus Biopharma Initiate International Patent Infringement Enforcement Actions Against Moderna BASEL, Switzerland and VANCOUVER, British Columbia and WARMINSTER, Pa., March 03, 2025 (GLOBE NEWSWIRE) - Genevant Sciences, a leading nucleic acid delivery company with world-class platforms and a robust lipid nanoparticle (LNP) patent portfolio (a subsidiary of Roiv

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 24, 2025 Arbutus Biophar

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 24, 2025 Arbutus Biopharma Corporation (Exact name of registrant as specified in its charter) British Columbia, Canada 001-34949 98-0597776 (State or Other Jurisdiction of In

Arbutus Announces Changes to Board of Directors and Appointment of Lindsay Androski as CEO

EXHIBIT 99.1 Arbutus Announces Changes to Board of Directors and Appointment of Lindsay Androski as CEO WARMINSTER, Pa., Feb. 25, 2025 (GLOBE NEWSWIRE) - Arbutus Biopharma Corporation (Nasdaq: ABUS) (“Arbutus” or the “Company”), a clinical-stage biopharmaceutical company focused on infectious disease, today announced changes to its board of directors and the appointment of Lindsay Androski, J.D.,

Principal Business Address of Employer

Exhibit 99.1 Covered Persons Roivant has a board of directors (such individuals, collectively, the "Covered Persons"). The name, present principal occupation and country of citizenship of each of the Covered Persons is set forth below, along with the principal business address of the employer of each of the Covered Persons. Name Principal Business Address of Employer Present Principal Occupation C

ABUS / Arbutus Biopharma Corporation / Whitefort Capital Master Fund, LP Activist Investment

SCHEDULE 13D/A 0001193805-24-000619 0001884931 XXXXXXXX LIVE 2 Common Shares, without par value 02/20/2025 true 0001447028 03879J100 Arbutus Biopharma Corp 701 VETERANS CIRCLE WARMINSTER PA 18974 DAVID SALANIC 212-259-4370 WHITEFORT CAPITAL MANAGEMENT, LP 12 East 49th Street, 40th Floor New York NY 10017 JOSEPH KAPLAN 212-259-4370 WHITEFORT CAPITAL MANAGEMENT, LP 12 East 49th Street, 40th Floor New York NY 10017 RYAN NEBEL 212-451-2300 OLSHAN FROME WOLOSKY LLP 1325 Avenue of the Americas New York NY 10019 PATRICIA OLASKER 416-863-0900 DAVIES WARD PHILLIPS & VINEBERG LLP 155 Wellington Street West Toronto A6 M5V 3J7 0001704387 N Whitefort Capital Master Fund, LP WC N E9 0.

Transactions in the Securities of the Issuer During the Past 60 Days

Exhibit 1 Transactions in the Securities of the Issuer During the Past 60 Days Nature of the Transaction Amount of Securities Purchased/(Sold) Price ($) Date of Purchase/Sale WHITEFORT CAPITAL MASTER FUND, LP Purchase of Common Stock 145,684 3.

ABUS / Arbutus Biopharma Corporation / Roivant Sciences Ltd. Activist Investment

SCHEDULE 13D/A 0001144204-15-016451 0001635088 XXXXXXXX LIVE 12 Common Shares, without par value 02/18/2025 false 0001447028 03879J100 Arbutus Biopharma Corp 701 Veterans Circle Warminster PA 18974 Derek J.

Principal Business Address of Employer

Exhibit 99.1 Covered Persons Roivant has a board of directors and executive officers (such individuals, collectively, the "Covered Persons"). The name, present principal occupation and country of citizenship of each of the Covered Persons is set forth below, along with the principal business address of the employer of each of the Covered Persons. Name Principal Business Address of Employer Present

EX-24

POWER OF ATTORNEY Know all by these presents that, that the undersigned does hereby makes, constitutes and appoints each of David C.

EX-24

POWER OF ATTORNEY Know all by these presents that, that the undersigned does hereby makes, constitutes and appoints each of David C.

EX-24

POWER OF ATTORNEY Know all by these presents that, that the undersigned does hereby makes, constitutes and appoints each of David C.

EX-99.1 CHARTER

EX-99.1 CHARTER 2 EXHIBITNO.99.1.txt EXHIBIT NO. 99.1 TO SCHEDULE 13G JOINT FILING AGREEMENT CUSIP No.03879J100 13G - EXHIBIT NO. 99.1 TO SCHEDULE 13G JOINT FILING AGREEMENT - February 03, 2025 - MORGAN STANLEY and Morgan Stanley Investment Management Inc. hereby agree that, unless differentiated, this Schedule 13G is filed on behalf of each of the parties. MORGAN STANLEY BY: /s/ Christopher O'Har

EX-99.2 OPIN COUNSEL

EX-99.2 OPIN COUNSEL 3 EXHIBITNO.99.2.txt EXHIBIT NO. 99.2 ITEM 7 INFORMATION CUSIP No.03879J100 13G - EXHIBIT NO. 99.2 - ITEM 7 INFORMATION The securities being reported on by Morgan Stanley as a parent holding company are owned, or may be deemed to be beneficially owned, by Morgan Stanley Investment Management Inc., a wholly-owned subsidiary of Morgan Stanley.

ABUS / Arbutus Biopharma Corporation / MORGAN STANLEY Passive Investment

SCHEDULE 13G/A 0000895421-24-000390 0000895421 XXXXXXXX LIVE 1 Common Shares 12/31/2024 0001447028 Arbutus Biopharma Corp 03879J100 701 VETERANS CIRCLE WARMINSTER PA 18974 Rule 13d-1(b) Morgan Stanley DE 0 21511348 0 21512037 21524661 N 11.

NASDAQ: ABUS www.arbutusbio.com January 13, 2025 Corporate Presentation © 2025 Arbutus Biopharma, Inc. Forward - Looking Statements This presentation contains forward - looking statements within the meaning of the U . S . Private Securities Litigatio

EXHIBIT 99.2 NASDAQ: ABUS www.arbutusbio.com January 13, 2025 Corporate Presentation © 2025 Arbutus Biopharma, Inc. Forward - Looking Statements This presentation contains forward - looking statements within the meaning of the U . S . Private Securities Litigation Reform Act of 1995 and Canadian securities laws . All statements that are not historical facts are hereby identified as forward - looki

Arbutus Provides 2025 Corporate and Financial Update Initiating Phase 2b clinical trial in first half of 2025 after achieving a meaningful functional cure rate in cHBV patients treated with imdusiran and interferon

EXHIBIT 99.1 Arbutus Provides 2025 Corporate and Financial Update Initiating Phase 2b clinical trial in first half of 2025 after achieving a meaningful functional cure rate in cHBV patients treated with imdusiran and interferon WARMINSTER, Pa., Jan. 13, 2025 (GLOBE NEWSWIRE) - Arbutus Biopharma Corporation (Nasdaq: ABUS) (“Arbutus” or the “Company”), a clinical-stage biopharmaceutical company leve

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 13, 2025 Arbutus Biopharm

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 13, 2025 Arbutus Biopharma Corporation (Exact name of registrant as specified in its charter) British Columbia, Canada 001-34949 98-0597776 (State or Other Jurisdiction of Inc

ARBUTUS BIOPHARMA CORPORATION 701 Veterans Circle Warminster, Pennsylvania 18974

ARBUTUS BIOPHARMA CORPORATION 701 Veterans Circle Warminster, Pennsylvania 18974 December 2, 2024 VIA EDGAR Office of Life Sciences Division of Corporation Finance U.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 15, 2024 Arbutus Biophar

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 15, 2024 Arbutus Biopharma Corporation (Exact name of registrant as specified in its charter) British Columbia, Canada 001-34949 98-0597776 (State or Other Jurisdiction of In

NASDAQ: ABUS www.arbutusbio.com November 15, 2024 Corporate Presentation © 2024 Arbutus Biopharma, Inc. Forward - Looking Statements This presentation contains forward - looking statements within the meaning of the U . S . Private Securities Litigati

EXHIBIT 99.3 NASDAQ: ABUS www.arbutusbio.com November 15, 2024 Corporate Presentation © 2024 Arbutus Biopharma, Inc. Forward - Looking Statements This presentation contains forward - looking statements within the meaning of the U . S . Private Securities Litigation Reform Act of 1995 and Canadian securities laws . All statements that are not historical facts are hereby identified as forward - look

Arbutus and Barinthus Bio Announce New Data from the IM-PROVE II Trial Showing that the Addition of Nivolumab Increased Rates of HBsAg Loss in People with Chronic Hepatitis B Significantly greater mean declines in HBsAg levels (p <0.017) were seen in

EXHIBIT 99.2 Arbutus and Barinthus Bio Announce New Data from the IM-PROVE II Trial Showing that the Addition of Nivolumab Increased Rates of HBsAg Loss in People with Chronic Hepatitis B Significantly greater mean declines in HBsAg levels (p <0.017) were seen in those receiving imdusiran, VTP-300 and low-dose nivolumab compared to other cohorts assessed previously 23% of participants receiving im

Arbutus’ Imdusiran Achieves Functional Cure in cHBV Patients when Combined with a Short Course of Interferon 50% of patients who had baseline HBsAg levels less than 1000 IU/mL achieved functional cure in Cohort A1 of the IM-PROVE I Phase 2a clinical

EXHIBIT 99.1 Arbutus’ Imdusiran Achieves Functional Cure in cHBV Patients when Combined with a Short Course of Interferon 50% of patients who had baseline HBsAg levels less than 1000 IU/mL achieved functional cure in Cohort A1 of the IM-PROVE I Phase 2a clinical trial Overall, in Cohort A1, 25% of patients achieved functional cure Data to be presented in late-breaker poster session at AASLD – The

LETTER

November 14, 2024 Michael McElhaugh Chief Executive Officer Arbutus Biopharma Corporation 701 Veterans Circle Warminster, PA 18974 Re: Arbutus Biopharma Corporation Registration Statement on Form S-3 Filed November 6, 2024 File No.

ABUS / Arbutus Biopharma Corporation / Two Seas Capital LP Passive Investment

SC 13G/A 1 formsc13ga-arbutus.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(b), (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-2 (Amendment No. 2)* Arbutus Biopharma Corporation (Name of Issuer) Common Shares, without par value (Title of Class of Securities) 03879J100 (

Form of Indenture (filed herewith).

Exhibit 4.5 INDENTURE DATED AS OF           , 20 BETWEEN ARBUTUS BIOPHARMA CORPORATION as Issuer, AND as Trustee Providing for Issuance of Debt Securities in Series Table of Contents Page ARTICLE I. DEFINITIONS AND OTHER PROVISIONS OF GENERAL APPLICATION 1 Section 1.01 Definitions 1 Section 1.02 Compliance Certificates and Opinions 6 Section 1.03 Form of Documents Delivered to Trustee 6 Section 1.

As filed with the Securities and Exchange Commission on November 6, 2024

TABLE OF CONTENTS As filed with the Securities and Exchange Commission on November 6, 2024 Registration No.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period from to Commission File Number: 001-34949 ARBUTUS BIOPHARM

Filing Fee Table (filed herewith).

Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) Arbutus Biopharma Corporation (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered (1) Proposed Maximum Offering Price Per Unit (2) Maximum Aggregate Offering Price Fee Rate Amount of Re

NASDAQ: ABUS www.arbutusbio.com November 6, 2024 Corporate Presentation © 2024 Arbutus Biopharma, Inc. Forward - Looking Statements This presentation contains forward - looking statements within the meaning of the U . S . Private Securities Litigatio

Exhibit 99.2 NASDAQ: ABUS www.arbutusbio.com November 6, 2024 Corporate Presentation © 2024 Arbutus Biopharma, Inc. Forward - Looking Statements This presentation contains forward - looking statements within the meaning of the U . S . Private Securities Litigation Reform Act of 1995 and Canadian securities laws . All statements that are not historical facts are hereby identified as forward - looki

Arbutus Reports Third Quarter 2024 Financial Results and Provides Corporate Update Imdusiran data from IM-PROVE I and IM-PROVE II Phase 2a clinical trials to be presented at upcoming AASLD - The Liver Meeting 2024 Multiple-ascending doses of AB-101 i

EXHIBIT 99.1 Arbutus Reports Third Quarter 2024 Financial Results and Provides Corporate Update Imdusiran data from IM-PROVE I and IM-PROVE II Phase 2a clinical trials to be presented at upcoming AASLD - The Liver Meeting 2024 Multiple-ascending doses of AB-101 in healthy subjects in the Phase 1a/1b clinical trial were generally safe and well-tolerated with evidence of receptor occupancy Now dosin

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 6, 2024 Arbutus Biopharm

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 6, 2024 Arbutus Biopharma Corporation (Exact name of registrant as specified in its charter) British Columbia, Canada 001-34949 98-0597776 (State or Other Jurisdiction of Inc

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 15, 2024 Arbutus Biopharm

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 15, 2024 Arbutus Biopharma Corporation (Exact name of registrant as specified in its charter) British Columbia, Canada 001-34949 98-0597776 (State or Other Jurisdiction of Inc

Arbutus Announces Multiple Abstracts Highlighting Imdusiran Data Accepted for Presentation at AASLD - The Liver Meeting® 2024

EXHIBIT 99.1 Arbutus Announces Multiple Abstracts Highlighting Imdusiran Data Accepted for Presentation at AASLD - The Liver Meeting® 2024 WARMINSTER, Pa., Oct. 15, 2024 (GLOBE NEWSWIRE) - Arbutus Biopharma Corporation (Nasdaq: ABUS), (“Arbutus” or the “Company”) a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop a functional cure for people with chro

First Amendment to Executive Employment Agreement, dated October 11, 2024, by and between Michael J. Sofia and Arbutus Biopharma, Inc.

FIRST AMENDMENT TO EXECUTIVE EMPLOYMENT AGREEMENT This First Amendment to Executive Employment Agreement (this “Amendment”) is made effective as of October 11, 2024 (the “Effective Date”) by and between Arbutus Biopharma, Inc.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 11, 2024 Arbutus Biopharm

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 11, 2024 Arbutus Biopharma Corporation (Exact name of registrant as specified in its charter) British Columbia, Canada 001-34949 98-0597776 (State or other jurisdiction of inc

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period from to Commission File Number: 001-34949 ARBUTUS BIOPHARMA COR

As filed with the Securities and Exchange Commission on August 8, 2024

As filed with the Securities and Exchange Commission on August 8, 2024 Registration No.

Filing Fee Table

Exhibit 107 Calculation of Filing Fee Table Form S-8 (Form Type) Arbutus Biopharma Corporation (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered(1) Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity Common Shares, without par value, issuable under the Arbutus Biopharma Corporation 2016 Omnibus Share and Incentive Plan Other 9,500,000(2) $3.

Regulation FD Disclosure

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 5, 2024 Arbutus Biopharma Corporation (Exact name of registrant as specified in its charter) British Columbia, Canada 001-34949 98-0597776 (State or other jurisdiction of incor

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 1, 2024 Arbutus Biopharma

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 1, 2024 Arbutus Biopharma Corporation (Exact name of registrant as specified in its charter) British Columbia, Canada 001-34949 98-0597776 (State or Other Jurisdiction of Incor

Arbutus Reports Second Quarter 2024 Financial Results and Provides Corporate Update End-of-treatment data presented at the EASL Congress from two Phase 2a clinical trials supports advancing imdusiran as a potential cornerstone in a HBV functional cur

EXHIBIT 99.1 Arbutus Reports Second Quarter 2024 Financial Results and Provides Corporate Update End-of-treatment data presented at the EASL Congress from two Phase 2a clinical trials supports advancing imdusiran as a potential cornerstone in a HBV functional cure treatment regimen IM-PROVE I clinical trial demonstrated undetectable HBsAg in 33% of patients who were treated with 48 weeks of imdusi

NASDAQ: ABUS www.arbutusbio.com August 1, 2024 Corporate Presentation © 2024 Arbutus Biopharma, Inc. Forward - Looking Statements This presentation contains forward - looking statements within the meaning of the U . S . Private Securities Litigation

Exhibit 99.2 NASDAQ: ABUS www.arbutusbio.com August 1, 2024 Corporate Presentation © 2024 Arbutus Biopharma, Inc. Forward - Looking Statements This presentation contains forward - looking statements within the meaning of the U . S . Private Securities Litigation Reform Act of 1995 and Canadian securities laws . All statements that are not historical facts are hereby identified as forward - looking

ABUS / Arbutus Biopharma Corporation / MORGAN STANLEY - MS INITIAL Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No.)* Arbutus Biopharma Corp - (Name of Issuer) Common Shares - (Title of Class of Securities) 03879J100 - (CUSIP Number) May 31, 2024 - (Date Of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which thi

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 6, 2024 Arbutus Biopharma Co

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 6, 2024 Arbutus Biopharma Corporation (Exact name of registrant as specified in its charter) British Columbia, Canada 001-34949 98-0597776 (State or Other Jurisdiction of Incorpo

NASDAQ: ABUS www.arbutusbio.com June 6, 2024 Corporate Presentation © 2024 Arbutus Biopharma, Inc. Forward - Looking Statements This presentation contains forward - looking statements within the meaning of the U . S . Private Securities Litigation Re

Exhibit 99.2 NASDAQ: ABUS www.arbutusbio.com June 6, 2024 Corporate Presentation © 2024 Arbutus Biopharma, Inc. Forward - Looking Statements This presentation contains forward - looking statements within the meaning of the U . S . Private Securities Litigation Reform Act of 1995 and Canadian securities laws . All statements that are not historical facts are hereby identified as forward - looking s

Treatment with Arbutus’ Imdusiran and VTP-300 Achieves Statistical Significance in Lowering HBsAg Levels Data highlighted in oral presentation at the European Association for the Study of the Liver (EASL) Congress

EXHIBIT 99.1 Treatment with Arbutus’ Imdusiran and VTP-300 Achieves Statistical Significance in Lowering HBsAg Levels Data highlighted in oral presentation at the European Association for the Study of the Liver (EASL) Congress WARMISTER, Pa., June 06, 2024 (GLOBE NEWSWIRE) - Arbutus Biopharma Corporation (Nasdaq: ABUS) (“Arbutus” or the “Company”), a clinical-stage biopharmaceutical company levera

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 5, 2024 Arbutus Biopharma Co

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 5, 2024 Arbutus Biopharma Corporation (Exact name of registrant as specified in its charter) British Columbia, Canada 001-34949 98-0597776 (State or Other Jurisdiction of Incorpo

Arbutus’ Imdusiran with Short Course Interferon Achieves Sustained Undetectable HBsAg, a Necessity for HBV Functional Cure At the end of treatment, 33.3% of patients receiving imdusiran for 48 weeks, interferon (IFN) for 24 weeks and ongoing nucleosi

EXHIBIT 99.1 Arbutus’ Imdusiran with Short Course Interferon Achieves Sustained Undetectable HBsAg, a Necessity for HBV Functional Cure At the end of treatment, 33.3% of patients receiving imdusiran for 48 weeks, interferon (IFN) for 24 weeks and ongoing nucleoside analogue (NA) therapy achieved undetectable levels of HBsAg that were maintained in 100% of these patients 24 weeks after completing i

NASDAQ: ABUS www.arbutusbio.com June 5, 2024 Corporate Presentation © 2024 Arbutus Biopharma, Inc. Forward - Looking Statements This presentation contains forward - looking statements within the meaning of the U . S . Private Securities Litigation Re

Exhibit 99.2 NASDAQ: ABUS www.arbutusbio.com June 5, 2024 Corporate Presentation © 2024 Arbutus Biopharma, Inc. Forward - Looking Statements This presentation contains forward - looking statements within the meaning of the U . S . Private Securities Litigation Reform Act of 1995 and Canadian securities laws . All statements that are not historical facts are hereby identified as forward - looking s

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits, Submission of Matters to a Vote of Security Holders

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 22, 2024 Arbutus Biopharma Corporation (Exact name of registrant as specified in its charter) British Columbia, Canada 001-34949 98-0597776 (State or other jurisdiction of incorpo

Arbutus Biopharma Corporation 2016 Omnibus Share and Incentive Plan, as supplemented and amended

EXHIBIT 10.1 ARBUTUS BIOPHARMA CORPORATION 2016 OMNIBUS SHARE AND INCENTIVE PLAN (as adopted by the board of directors on April 6, 2016 and approved by the shareholders on May 19, 2016; and as supplemented by the Committee on May 9, 2019) Section 1. Purpose The purpose of the Plan is to promote the interests of the Company by aiding the Company in attracting and retaining employees, officers, cons

Arbutus to Present Imdusiran Data at EASL Congress 2024

EXHIBIT 99.1 Arbutus to Present Imdusiran Data at EASL Congress 2024 WARMINSTER, Pa., May 22, 2024 (GLOBE NEWSWIRE) - Arbutus Biopharma Corporation (Nasdaq: ABUS) (“Arbutus” or the “Company”), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop a functional cure for people with chronic hepatitis B virus (cHBV) infection, today announced that two abstra

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 22, 2024 Arbutus Biopharma Co

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 22, 2024 Arbutus Biopharma Corporation (Exact name of registrant as specified in its charter) British Columbia, Canada 001-34949 98-0597776 (State or Other Jurisdiction of Incorpo

ABUS / Arbutus Biopharma Corporation / Whitefort Capital Management, LP - AMENDMENT NO. 1 TO THE SCHEDULE 13D Activist Investment

SC 13D/A 1 sc13da11412500205172024.htm AMENDMENT NO. 1 TO THE SCHEDULE 13D UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Rule 13d-101) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-2(a) (Amendment No. 1)1 Arbutus Biopharma Corporation (Name of Issuer) Common Shares, without par va

ABUS / Arbutus Biopharma Corporation / Whitefort Capital Management, LP - PRESS RELEASE, DATED MAY 17, 2024 Activist Investment

begin 644 ex991to13da114125002051724.pdf M)5!$1BTQ+C8-)>+CS],-"C0P(# @;V)J#3P\+TQI;F5AF4@-S@O5'EP92]84F5F+U=;,2 S(#%=/CYS=')E86T-"FC>8F)D M8!!@8&)@8&8&D0R!()+Q,XAD<0&S34$D:P98Q I,O@>3F\$D*UCO3C![#HAD MT@:3$+UI(%)]+HA,X0"+1(%(62$@R6BK"23?C.P 1TPW:P[0R,5";,S!> M^@008 #T] ],#0IE;F1S=')E86T-96YD;V)J#7-T87)T>')E9@T*, T*)25% M3T8-"B @(" @(" @#0HW-R P(&]B:@T\/"]&:6QT97(O1FQA=&5$96-O9&4O M22 R,#0O3" Q.#@O

JOINT FILING AGREEMENT

EX-99.1 2 ex991tosc13d14125002050624.htm JOINT FILING AGREEMENT Exhibit 99.1 JOINT FILING AGREEMENT In accordance with Rule 13d-1(k)(1)(iii) under the Securities Exchange Act of 1934, as amended, the persons named below agree to the joint filing on behalf of each of them of a Statement on Schedule 13D (including amendments thereto) with respect to the Common Shares, without par value, of Arbutus B

ABUS / Arbutus Biopharma Corporation / Whitefort Capital Management, LP - THE SCHEDULE 13D Activist Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Rule 13d-101) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-2(a) (Amendment No. )1 Arbutus Biopharma Corporation (Name of Issuer) Common Shares, without par value (Title of Class of Securities) 03879J100 (CUSIP Number) DAVID SALANIC Jo

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 1, 2024 Arbutus Biopharma Cor

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 1, 2024 Arbutus Biopharma Corporation (Exact name of registrant as specified in its charter) British Columbia, Canada 001-34949 98-0597776 (State or Other Jurisdiction of Incorpor

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period from to Commission File Number: 001-34949 ARBUTUS BIOPHARMA CO

Arbutus Announces Retirement of Chief Scientific Officer, Michael J. Sofia, PhD, Effective December 31, 2024

EXHIBIT 99.1 Arbutus Announces Retirement of Chief Scientific Officer, Michael J. Sofia, PhD, Effective December 31, 2024 WARMINSTER, Pa., May 02, 2024 (GLOBE NEWSWIRE) - Arbutus Biopharma Corporation (Nasdaq: ABUS) (“Arbutus” or the “Company”), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop a functional cure for people with chronic hepatitis B vi

Arbutus Reports First Quarter 2024 Financial Results and Provides Corporate Update End-of-treatment data from two Phase 2a combination clinical trials with imdusiran to be presented at the EASL Congress in June 2024 Preliminary data from the single-d

EXHIBIT 99.1 Arbutus Reports First Quarter 2024 Financial Results and Provides Corporate Update End-of-treatment data from two Phase 2a combination clinical trials with imdusiran to be presented at the EASL Congress in June 2024 Preliminary data from the single-dose portion of the AB-101-001 clinical trial show that AB-101 was generally well-tolerated and bound to the receptor target in healthy su

NASDAQ: ABUS www.arbutusbio.com May 2, 2024 Corporate Presentation © 2024 Arbutus Biopharma, Inc. Forward - Looking Statements © 2024 Arbutus Biopharma, Inc. 2 This presentation contains forward - looking statements within the meaning of the U . S .

Exhibit 99.2 NASDAQ: ABUS www.arbutusbio.com May 2, 2024 Corporate Presentation © 2024 Arbutus Biopharma, Inc. Forward - Looking Statements © 2024 Arbutus Biopharma, Inc. 2 This presentation contains forward - looking statements within the meaning of the U . S . Private Securities Litigation Reform Act of 1995 and Canadian securities laws . All statements that are not historical facts are hereby i

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 2, 2024 Arbutus Biopharma Cor

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 2, 2024 Arbutus Biopharma Corporation (Exact name of registrant as specified in its charter) British Columbia, Canada 001-34949 98-0597776 (State or Other Jurisdiction of Incorpor

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant  ☐ Check the appropriate box:  ☐ Preliminary Proxy Statement  ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy St

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant  ☐ Check the appropriate box:  ☐ Preliminary Proxy Statement  ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ D

Arbutus Biopharma Announces Claim Construction Ruling in its Ongoing Patent Infringement Lawsuit Against Moderna

EX-99.1 2 exh991.htm PRESS RELEASE EXHIBIT 99.1 Arbutus Biopharma Announces Claim Construction Ruling in its Ongoing Patent Infringement Lawsuit Against Moderna WARMINSTER, Pa., April 04, 2024 (GLOBE NEWSWIRE) - Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop a functional cure for people with chronic he

Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 4, 2024 Arbutus Biopharma Corporation (Exact name of registrant as specified in its charter) British Columbia, Canada 001-34949 98-0597776 (State or Other Jurisdiction of Incorp

Separation and Release Agreement, dated effective as of July 7, 2023, between Arbutus Biopharma Corporation and Elizabeth A. Howard.

Exhibit 10.34 Separation and Release Agreement By and Between Elizabeth A. Howard, J.D., Ph.D. and Arbutus Biopharma Corporation. This Confidential Separation and Release Agreement (“Agreement”) is entered into between Elizabeth A. Howard, J.D., Ph.D. (“Executive”) and Arbutus Biopharma Corporation and is in consideration of the mutual undertakings set forth below. Executive and Arbutus Biopharma

List of Subsidiaries.

Exhibit 21.1 Arbutus Biopharma Corporation List of Subsidiaries Name Jurisdiction Arbutus Biopharma Inc. Delaware, United States of America

Tenant Estoppel Certificate between Arbutus Biopharma, Inc. and Novitia Equities, LLC dated October 23, 2023.

Estoppel Certificate THIS TENANT ESTOPPEL CERTIFICATE ("Certificate"), dated as of October 23, 2023, is executed by ARBUTUS BIOPHARMA, INC.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended December 31, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period from to Commission File Number: 001-34949 Arbutus Biopharma Corpora

Arbutus Biopharma Corporation Incentive Compensation Recovery Policy.

Exhibit 97 Arbutus Biopharma Corporation Incentive Compensation Recovery Policy Adopted by the Board of Directors (the “Board”) of Arbutus Biopharma Corporation (the “Company”) on October 18, 2023 The Company is committed to conducting business in accordance with the highest ethical and legal standards, and the Board believes that a culture that emphasizes integrity and accountability is in the best interests of the Company and its shareholders and essential to the Company’s success.

Form of Arbutus Biopharma Corporation Indemnity Agreement

Exhibit 10.1 INDEMNITY AGREEMENT THIS AGREEMENT has been entered into as of the day of , 20 BETWEEN: ARBUTUS BIOPHARMA CORPORATION, a company duly incorporated under the laws of the Province of British Columbia, and having an office at 701 Veterans Circle, Warminster, PA 18974 (the “Indemnitor”) AND: [insert name], with an address c/o 701 Veterans Circle, Warminster, PA 18974 USA (the “Indemnitee”

18, the Third Amendment to Executive Employment Agreement dated November 1, 2022 and the Fourth Amendment to the Executive Employment Agreement, dated January 1, 2024 (incorporated her

Printed Name: Michael J. McElhaugh

Exhibit 4.1

Exhibit 4.1 DESCRIPTION OF THE REGISTRANT’S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 As of the date of the Annual Report on Form 10-K of which this exhibit forms a part, the only class of securities of Arbutus Biopharma Corporation (“we,” “us” and “our”) registered under Section 12 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), i

Subordination,Non-Disturbance and Attornment Agreement by and among, the Company, Univest Bank and Trust Co., and Veterans Circle Group, LLC dated December 12, 2023.

Exhibit 10.16 PREPARED BY AND RECORD AND RETURN TO: Christopher W. Rosenbleeth, Esquire Stradley Ronon Stevens & Young, LLP 2600 One Commerce Square Philadelphia, PA 19103 Location: 701 Veterans Circle Municipality: Warminster Township County: Bucks State: Pennsylvania SUBORDINATION, NON-DISTURBANCE AND ATTORNMENT AGREEMENT THIS SUBORDINATION, NON-DISTURBANCE AND ATTORNMENT AGREEMENT (this “Agreem

Consulting Agreement, dated effective July 7, 2023, by and between Elizabeth A. Howard and Arbutus Biopharma Corporation.

Exhibit 10.35 CONSULTING AGREEMENT Consultant Name: Elizabeth A. Howard, J.D., Ph.D. (“Consultant”) Effective Date: July 7, 2023 As a condition of becoming retained by Arbutus Biopharma Corporation, a British Columbia corporation, Arbutus Biopharma Inc., a Delaware Corporation, or any of its current or future subsidiaries, affiliates, successors or assigns (collectively, “Arbutus”), and in conside

NASDAQ: ABUS www.arbutusbio.com February 29, 2024 Corporate Presentation © 2024 Arbutus Biopharma, Inc. Forward - Looking Statements This presentation contains forward - looking statements within the meaning of the U . S . Private Securities Litigati

Exhibit 99.2 NASDAQ: ABUS www.arbutusbio.com February 29, 2024 Corporate Presentation © 2024 Arbutus Biopharma, Inc. Forward - Looking Statements This presentation contains forward - looking statements within the meaning of the U . S . Private Securities Litigation Reform Act of 1995 and Canadian securities laws . All statements that are not historical facts are hereby identified as forward - look

Financial Statements and Exhibits, Results of Operations and Financial Condition, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 29, 2024 Arbutus Biopharma Corporation (Exact name of registrant as specified in its charter) British Columbia, Canada 001-34949 98-0597776 (State or Other Jurisdiction of In

Arbutus Reports Fourth Quarter and Year End 2023 Financial Results and Provides Corporate Update On-track to report key clinical data in 2024 from two on-going Phase 2a clinical trials with imdusiran and the Phase 1a/1b clinical trial with AB-101 Pla

EXHIBIT 99.1 Arbutus Reports Fourth Quarter and Year End 2023 Financial Results and Provides Corporate Update On-track to report key clinical data in 2024 from two on-going Phase 2a clinical trials with imdusiran and the Phase 1a/1b clinical trial with AB-101 Plans to initiate a third Phase 2a clinical trial with imdusiran in first half of 2024 Claim Construction for Moderna LNP litigation occurre

ABUS / Arbutus Biopharma Corporation / Whitefort Capital Management, LP Passive Investment

SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1 )* Arbutus Biopharma Corporation (Name of Issuer) Common Shares, without par value (Title of Class of Securities) 03879J100 (CUSIP Number) December 31, 2023 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant

ABUS / Arbutus Biopharma Corporation / Two Seas Capital LP Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(b), (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-2 (Amendment No. 1)* Arbutus Biopharma Corporation (Name of Issuer) Common Shares, without par value (Title of Class of Securities) 03879J100 (CUSIP Number) December 31, 2023 (D

ABUS / Arbutus Biopharma Corporation / BlackRock Inc. Passive Investment

ca03879j1003021224.txt SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No: 1) Arbutus Biopharma Corp - (Name of Issuer) Common Stock - (Title of Class of Securities) BZ0QMB7 - (SEDOL Number) December 31, 2023 - (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant

Arbutus Announces 2024 Corporate Objectives and Provides Financial Update Additional data from two on-going Phase 2a clinical trials evaluating imdusiran, our RNAi therapeutic, as a cornerstone therapy in combination with other compounds expected in

EXHIBIT 99.1 Arbutus Announces 2024 Corporate Objectives and Provides Financial Update Additional data from two on-going Phase 2a clinical trials evaluating imdusiran, our RNAi therapeutic, as a cornerstone therapy in combination with other compounds expected in 2024 Initiation of a third Phase 2a clinical trial evaluating imdusiran and an approved PD-L1 monoclonal antibody expected in 1H 2024 Pre

NASDAQ: ABUS www.arbutusbio.com January 8, 2024 Corporate Presentation © 2024 Arbutus Biopharma, Inc. Forward - Looking Statements This presentation contains forward - looking statements within the meaning of the U . S . Private Securities Litigation

Exhibit 99.2 NASDAQ: ABUS www.arbutusbio.com January 8, 2024 Corporate Presentation © 2024 Arbutus Biopharma, Inc. Forward - Looking Statements This presentation contains forward - looking statements within the meaning of the U . S . Private Securities Litigation Reform Act of 1995 and Canadian securities laws . All statements that are not historical facts are hereby identified as forward - lookin

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 8, 2024 Arbutus Biopharma

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 8, 2024 Arbutus Biopharma Corporation (Exact name of registrant as specified in its charter) British Columbia, Canada 001-34949 98-0597776 (State or Other Jurisdiction of Inco

Separation and Release Agreement, dated December 31, 2023, by and between William Collier and Arbutus Biopharma Corporation

Exhibit 10.1 Separation and Release Agreement By and Between William Collier and Arbutus Biopharma Corporation. This Confidential Separation and Release Agreement (“Agreement”) is entered into between William Collier (“Executive”) and Arbutus Biopharma Corporation and is in consideration of the mutual undertakings set forth below. Executive and Arbutus Biopharma Corporation have mutually agreed to

Consulting Agreement, effective December 31, 2023, by and between William Collier and Arbutus Biopharma Corporation

Exhibit 10.2 CONSULTING AGREEMENT Consultant Name: William Collier (“Consultant”) Effective Date: December 31, 2023 As a condition of becoming retained by Arbutus Biopharma Corporation, a British Columbia corporation, Arbutus Biopharma Inc., a Delaware Corporation, or any of its current or future subsidiaries, affiliates, successors or assigns (collectively, “Arbutus”), and in consideration of Con

Fourth Amendment to Executive Employment Agreement, dated January 1, 2024, by and between Michael McElhaugh and Arbutus Biopharma, Inc.

Exhibit 10.3 FOURTH AMENDMENT TO EXECUTIVE EMPLOYMENT AGREEMENT This Fourth Amendment to Executive Employment Agreement (this “Amendment”) is made effective as of January 1, 2024 (the “Effective Date”) by and between Arbutus Biopharma, Inc. (the “Company”), and Michael McElhaugh (the “Executive”) (together the “Parties”). RECITALS A. The Company and the Executive have entered into an Executive Emp

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 31, 2023 Arbutus Biophar

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 31, 2023 Arbutus Biopharma Corporation (Exact name of registrant as specified in its charter) British Columbia, Canada 001-34949 98-0597776 (State or other jurisdiction of in

ABUS / Arbutus Biopharma Corp / Two Seas Capital LP Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(b), (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-2 (Amendment No. )* Arbutus Biopharma Corporation (Name of Issuer) Common Shares, without par value (Title of Class of Securities) 03879J100 (CUSIP Number) N/A (Date of Event wh

Arbutus Biopharma and Barinthus Bio Present Preliminary Data from Phase 2a Clinical Trial Combining Imdusiran with VTP-300 at AASLD - The Liver Meeting® The combination of imdusiran and VTP-300 provides a meaningful reduction of HBsAg levels that are

EXHIBIT 99.1 Arbutus Biopharma and Barinthus Bio Present Preliminary Data from Phase 2a Clinical Trial Combining Imdusiran with VTP-300 at AASLD - The Liver Meeting® The combination of imdusiran and VTP-300 provides a meaningful reduction of HBsAg levels that are maintained well below baseline Preliminary data in subset of patients given imdusiran and then VTP-300 show early signs of immune activa

NASDAQ: ABUS www.arbutusbio.com November 9, 2023 Corporate Presentation © 2023 Arbutus Biopharma, Inc. Forward - Looking Statements This presentation contains forward - looking statements within the meaning of the U . S . Private Securities Litigatio

Exhibit 99.2 NASDAQ: ABUS www.arbutusbio.com November 9, 2023 Corporate Presentation © 2023 Arbutus Biopharma, Inc. Forward - Looking Statements This presentation contains forward - looking statements within the meaning of the U . S . Private Securities Litigation Reform Act of 1995 and Canadian securities laws . All statements that are not historical facts are hereby identified as forward - looki

Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 9, 2023 Arbutus Biopharma Corporation (Exact name of registrant as specified in its charter) British Columbia, Canada 001-34949 98-0597776 (State or Other Jurisdiction of Inc

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period from to Commission File Number: 001-34949 ARBUTUS BIOPHARM

Arbutus Reports Third Quarter 2023 Financial Results and Provides Corporate Update Multiple data presentations upcoming at AASLD – The Liver Meeting®, including preliminary data from Phase 2a clinical trial combining imdusiran, our RNAi therapeutic,

EXHIBIT 99.1 Arbutus Reports Third Quarter 2023 Financial Results and Provides Corporate Update Multiple data presentations upcoming at AASLD – The Liver Meeting®, including preliminary data from Phase 2a clinical trial combining imdusiran, our RNAi therapeutic, with VTP-300, an HBV antigen-specific immunotherapy Dosing continues in two Phase 2a combination clinical trials with imdusiran and in a

Financial Statements and Exhibits, Results of Operations and Financial Condition, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 7, 2023 Arbutus Biopharma Corporation (Exact name of registrant as specified in its charter) British Columbia, Canada 001-34949 98-0597776 (State or Other Jurisdiction of Inc

Arbutus Announces CEO, William Collier, to Retire December 31, 2023 Michael J. McElhaugh, Arbutus Co-founder and COO, to Serve as Interim CEO

EXHIBIT 99.1 Arbutus Announces CEO, William Collier, to Retire December 31, 2023 Michael J. McElhaugh, Arbutus Co-founder and COO, to Serve as Interim CEO WARMINSTER, Pa., Nov. 07, 2023 (GLOBE NEWSWIRE) - Arbutus Biopharma Corporation (Nasdaq: ABUS) (“Arbutus” or the “Company”), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop a cure for people with

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 1, 2023 Arbutus Biopharma Corporation (Exact name of registrant as specified in its charter) British Columbia, Canada 001-34949 98-0597776 (State or Other Jurisdiction of Inc

NASDAQ: ABUS www.arbutusbio.com November 7, 2023 Corporate Presentation © 2023 Arbutus Biopharma, Inc. Forward - Looking Statements This presentation contains forward - looking statements within the meaning of the U . S . Private Securities Litigatio

Exhibit 99.2 NASDAQ: ABUS www.arbutusbio.com November 7, 2023 Corporate Presentation © 2023 Arbutus Biopharma, Inc. Forward - Looking Statements This presentation contains forward - looking statements within the meaning of the U . S . Private Securities Litigation Reform Act of 1995 and Canadian securities laws . All statements that are not historical facts are hereby identified as forward - looki

Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 11, 2023 Arbutus Biopharma Corporation (Exact name of registrant as specified in its charter) British Columbia, Canada 001-34949 98-0597776 (State or Other Jurisdiction of Inc

Arbutus Announces Multiple Abstracts Accepted for Presentation at AASLD - The Liver Meeting® 2023 Imdusiran data will be highlighted in late breaking presentation

EXHIBIT 99.1 Arbutus Announces Multiple Abstracts Accepted for Presentation at AASLD - The Liver Meeting® 2023 Imdusiran data will be highlighted in late breaking presentation WARMINSTER, Pa., Oct. 11, 2023 (GLOBE NEWSWIRE) - Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop novel therapeutics that target

Arbutus Announces Pipeline Updates and Dosing of the First Subject in the Phase 1a/1b Clinical Trial with AB-101; Cash Runway Extended Progressing development of hepatitis B virus (HBV) compounds imdusiran (AB-729) and AB-101, an oral PD-L1 inhibitor

EXHIBIT 99.1 Arbutus Announces Pipeline Updates and Dosing of the First Subject in the Phase 1a/1b Clinical Trial with AB-101; Cash Runway Extended Progressing development of hepatitis B virus (HBV) compounds imdusiran (AB-729) and AB-101, an oral PD-L1 inhibitor Discontinuing all coronavirus and oral RNA destabilizer programs, including AB-343 and AB-161 Extending cash runway through Q3 2025 WARM

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 11, 2023 Arbutus Biopha

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 11, 2023 Arbutus Biopharma Corporation (Exact name of registrant as specified in its charter) British Columbia, Canada 001-34949 98-0597776 (State or Other Jurisdiction of I

ABUS / Arbutus Biopharma Corp / Whitefort Capital Management, LP Passive Investment

SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Arbutus Biopharma Corporation (Name of Issuer) Common Shares, without par value (Title of Class of Securities) 03879J100 (CUSIP Number) September 1, 2023 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to

NASDAQ: ABUS www.arbutusbio.com September 11, 2023 Corporate Presentation © 2023 Arbutus Biopharma, Inc. Forward - Looking Statements This presentation contains forward - looking statements within the meaning of the U . S . Private Securities Litigat

EXHIBIT 99.2 NASDAQ: ABUS www.arbutusbio.com September 11, 2023 Corporate Presentation © 2023 Arbutus Biopharma, Inc. Forward - Looking Statements This presentation contains forward - looking statements within the meaning of the U . S . Private Securities Litigation Reform Act of 1995 and Canadian securities laws . All statements that are not historical facts are hereby identified as forward - loo

Arbutus Reports Second Quarter 2023 Financial Results and Corporate Update Regulatory approval received in New Zealand to advance AB-101, our oral PD-L1 inhibitor, into a Phase 1 clinical trial with dosing to begin this quarter AB-729 (imdusiran), in

EXHIBIT 99.1 Arbutus Reports Second Quarter 2023 Financial Results and Corporate Update Regulatory approval received in New Zealand to advance AB-101, our oral PD-L1 inhibitor, into a Phase 1 clinical trial with dosing to begin this quarter AB-729 (imdusiran), in combination with pegylated interferon alfa-2a, in a Phase 2a clinical trial, was generally well tolerated and appears to result in conti

As filed with the Securities and Exchange Commission on August 3, 2023

As filed with the Securities and Exchange Commission on August 3, 2023 Registration No.

Option Agreement, dated July 10, 2023, by and between Arbutus Biopharma Corporation and J. Christopher Naftzger (incorporated herein by reference to Exhibit 10.3 to the Registrant’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2023, filed with the SEC on August 3, 2023).

Exhibit 10.3 UNLESS PERMITTED UNDER SECURITIES LEGISLATION, THE HOLDER OF THIS SECURITY MUST NOT TRADE THIS OPTION OR ANY OPTION SHARES ISSUABLE ON EXERCISE OF THIS OPTION BEFORE NOVEMBER 11, 2023 OPTION AGREEMENT - EMPLOYEES This Option Agreement (the “Agreement”) is entered into between Arbutus Biopharma Corporation (the “Company”) and J. Christopher Naftzger (the “Optionee”), and is being grant

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period from to Commission File Number: 001-34949 ARBUTUS BIOPHARMA COR

Filing Fee Table

Exhibit 107 Calculation of Filing Fee Table Form S-8 (Form Type) Arbutus Biopharma Corporation (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered(1) Proposed Maximum Offering Price Per Unit Proposed Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity Common Shares, without par value, issuable under the Arbutus Biopharma Corporation 2016 Omnibus Share and Incentive Plan Other 3,500,000(2) $2.

Executive Employment Agreement, dated effective as of July 10, 2023, between Arbutus Biopharma, Inc. and J. Christopher Naftzger (incorporated herein by reference to Exhibit 10.2 to the Registrant’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2023, filed with the SEC on August 3, 2023).

Exhibit 10.2 EXECUTIVE EMPLOYMENT AGREEMENT This Executive Employment Agreement (“Agreement”) is made effective as of July 10, 2023 (the “Effective Date”) by and between Arbutus Biopharma Inc. (the “Company”), and J. Christopher Naftzger (the “Executive”) (together the “Parties”). RECITALS A.WHEREAS, the Company desires to employ the Executive as General Counsel and Chief Compliance Officer in acc

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 3, 2023 Arbutus Biopharma

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 3, 2023 Arbutus Biopharma Corporation (Exact name of registrant as specified in its charter) British Columbia, Canada 001-34949 98-0597776 (State or Other Jurisdiction of Incor

Executive Employment Agreement, dated effective as of July 10, 2023, between Arbutus Biopharma, Inc. and Karen Sims, MD, PhD (incorporated herein by reference to Exhibit 10.1 to the Registrant’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2023, filed with the SEC on August 3, 2023).

Exhibit 10.1 EXECUTIVE EMPLOYMENT AGREEMENT This Executive Employment Agreement (“Agreement”), which supersedes in its entirety the Original Employment Agreement as defined below, is made effective as of July 10, 2023 (the “Effective Date”) by and between Arbutus Biopharma Inc. (the “Company”), and Karen Sims, MD, PhD (the “Executive”) (together the “Parties”) RECITALS A.WHEREAS, the Executive was

NASDAQ: ABUS www.arbutusbio.com August 3, 2023 Corporate Presentation © 2023 Arbutus Biopharma, Inc. Forward - Looking Statements This presentation contains forward - looking statements within the meaning of the U . S . Private Securities Litigation

Exhibit 99.2 NASDAQ: ABUS www.arbutusbio.com August 3, 2023 Corporate Presentation © 2023 Arbutus Biopharma, Inc. Forward - Looking Statements This presentation contains forward - looking statements within the meaning of the U . S . Private Securities Litigation Reform Act of 1995 and Canadian securities laws . All statements that are not historical facts are hereby identified as forward - looking

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 11, 2023 Arbutus Biopharma C

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 11, 2023 Arbutus Biopharma Corporation (Exact name of registrant as specified in its charter) British Columbia, Canada 001-34949 98-0597776 (State or Other Jurisdiction of Incorp

Arbutus Appoints Melissa V. Rewolinski, PhD to its Board of Directors

EXHIBIT 99.1 Arbutus Appoints Melissa V. Rewolinski, PhD to its Board of Directors WARMINSTER, Pa., July 12, 2023 (GLOBE NEWSWIRE) - Arbutus Biopharma Corporation (Nasdaq: ABUS) (“Arbutus” or the “Company”), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop novel therapeutics that target specific viral diseases, today announced the appointment of Mel

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 10, 2023 Arbutus Biopharma C

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 10, 2023 Arbutus Biopharma Corporation (Exact name of registrant as specified in its charter) British Columbia, Canada 001-34949 98-0597776 (State or Other Jurisdiction of Incorp

Arbutus Appoints Two New Executives Karen Sims, MD, PhD Promoted to Chief Medical Officer Christopher Naftzger Appointed as General Counsel and Chief Compliance Officer

EXHIBIT 99.1 Arbutus Appoints Two New Executives Karen Sims, MD, PhD Promoted to Chief Medical Officer Christopher Naftzger Appointed as General Counsel and Chief Compliance Officer WARMINSTER, Pa., July 10, 2023 (GLOBE NEWSWIRE) - Arbutus Biopharma Corporation (Nasdaq: ABUS) (“Arbutus” or the “Company”), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to dev

Arbutus Doses First Patient in Additional Treatment Arm of Phase 2a Triple Combination Clinical Trial that Includes a PD-1 Monoclonal Antibody Evaluating safety and efficacy of combining AB-729, VTP-300, nucleos(t)ide analogues and nivolumab (Opdivo®

EXHIBIT 99.1 Arbutus Doses First Patient in Additional Treatment Arm of Phase 2a Triple Combination Clinical Trial that Includes a PD-1 Monoclonal Antibody Evaluating safety and efficacy of combining AB-729, VTP-300, nucleos(t)ide analogues and nivolumab (Opdivo®) WARMINSTER, Pa., June 21, 2023 (GLOBE NEWSWIRE) - Arbutus Biopharma Corporation (Nasdaq: ABUS) (“Arbutus” or the “Company”), a clinical

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 21, 2023 Arbutus Biopharma C

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 21, 2023 Arbutus Biopharma Corporation (Exact name of registrant as specified in charter) British Columbia, Canada 001-34949 98-0597776 (State or other jurisdiction of incorporat

Arbutus Presents Preliminary AB-729 and Pegylated Interferon Alfa-2a Combination Data at the EASL Congress 2023 Treatment was generally well tolerated with continued HBsAg declines in some patients

EXHIBIT 99.1 Arbutus Presents Preliminary AB-729 and Pegylated Interferon Alfa-2a Combination Data at the EASL Congress 2023 Treatment was generally well tolerated with continued HBsAg declines in some patients WARMINSTER, Pa., June 21, 2023 (GLOBE NEWSWIRE) - Arbutus Biopharma Corporation (Nasdaq: ABUS) (“Arbutus” or the “Company”), a clinical-stage biopharmaceutical company leveraging its extens

Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 21, 2023 Arbutus Biopharma Corporation (Exact name of registrant as specified in charter) British Columbia, Canada 001-34949 98-0597776 (State or other jurisdiction of incorporat

Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 7, 2023 Arbutus Biopharma Corporation (Exact name of registrant as specified in its charter) British Columbia, Canada 001-34949 98-0597776 (State or Other Jurisdiction of Incorpo

Arbutus to Present AB-729 and AB-836 Data at EASL Congress 2023

EXHIBIT 99.1 Arbutus to Present AB-729 and AB-836 Data at EASL Congress 2023 WARMINSTER, Pa., June 07, 2023 (GLOBE NEWSWIRE) - Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop novel therapeutics that target specific viral diseases, today announced that two abstracts have been accepted for poster presenta

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits, Submission of Matters to a Vote of Security Holders

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 24, 2023 Arbutus Biopharma Corporation (Exact name of registrant as specified in its charter) British Columbia, Canada 001-34949 98-0597776 (State or other jurisdiction of incorpo

Arbutus Biopharma Corporation 2016 Omnibus Share and Incentive Plan, as supplemented and amended (incorporated herein by reference to Exhibit 10.1 to the Registrant’s Current Report on Form 8-K, filed with the SEC on May 30, 2023)

omnibusplan2016wamend5 EXHIBIT 10.1 ARBUTUS BIOPHARMA CORPORATION 2016 OMNIBUS SHARE AND INCENTIVE PLAN (as adopted by the board of directors on April 6, 2016 and approved by the shareholders on May 19, 2016; and as supplemented by the Committee on May 9, 2019) Section 1. Purpose The purpose of the Plan is to promote the interests of the Company by aiding the Company in attracting and retaining em

NASDAQ: ABUS www.arbutusbio.com May 4, 2023 Corporate Presentation © 2023 Arbutus Biopharma, Inc. Forward - Looking Statements This presentation contains forward - looking statements within the meaning of the U . S . Private Securities Litigation Ref

EXHIBIT 99.2 NASDAQ: ABUS www.arbutusbio.com May 4, 2023 Corporate Presentation © 2023 Arbutus Biopharma, Inc. Forward - Looking Statements This presentation contains forward - looking statements within the meaning of the U . S . Private Securities Litigation Reform Act of 1995 and Canadian securities laws . All statements that are not historical facts are hereby identified as forward - looking st

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period from to Commission File Number: 001-34949 ARBUTUS BIOPHARMA CO

Financial Statements and Exhibits, Results of Operations and Financial Condition, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 4, 2023 Arbutus Biopharma Corporation (Exact name of registrant as specified in its charter) British Columbia, Canada 001-34949 98-0597776 (State or Other Jurisdiction of Incorpor

Arbutus Reports First Quarter 2023 Financial Results and Corporate Update Additional AB-729 off-treatment data highlighted in an oral presentation at the Global Hepatitis Summit 2023 Dosed first subject in Phase 1 clinical trial with oral RNA Destabi

EXHIBIT 99.1 Arbutus Reports First Quarter 2023 Financial Results and Corporate Update Additional AB-729 off-treatment data highlighted in an oral presentation at the Global Hepatitis Summit 2023 Dosed first subject in Phase 1 clinical trial with oral RNA Destabilizer, AB-161 Filed patent infringement lawsuit against Pfizer and BioNTech seeking compensation for use of unlicensed patented technolog

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 27, 2023 Arbutus Biopharma

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 27, 2023 Arbutus Biopharma Corporation (Exact name of registrant as specified in its charter) British Columbia, Canada 001-34949 98-0597776 (State or Other Jurisdiction of Incor

Arbutus Provides AB-729 Clinical Data and AB-161 Preclinical Data as Oral Presentations at the Global Hepatitis Summit 2023 Seven patients with cHBV remain off all treatment and continue to maintain low levels of HBV DNA and HBsAg for at least one an

EXHIBIT 99.1 Arbutus Provides AB-729 Clinical Data and AB-161 Preclinical Data as Oral Presentations at the Global Hepatitis Summit 2023 Seven patients with cHBV remain off all treatment and continue to maintain low levels of HBV DNA and HBsAg for at least one and half years post- AB-729 treatment AB-161 provides robust anti-HBV activity including suppression of HBV RNA and HBsAg production in pre

Arbutus Announces FDA Clinical Hold on IND Application for AB-101, an oral PD-L1 inhibitor

EXHIBIT 99.1 Arbutus Announces FDA Clinical Hold on IND Application for AB-101, an oral PD-L1 inhibitor WARMINSTER, Pa., April 25, 2023 (GLOBE NEWSWIRE) - Arbutus Biopharma Corporation (Nasdaq: ABUS) (“Arbutus” or the “Company”), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop novel therapeutics that target specific viral diseases, today announced

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 25, 2023 Arbutus Biopharma

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 25, 2023 Arbutus Biopharma Corporation (Exact name of registrant as specified in its charter) British Columbia, Canada 001-34949 98-0597776 (State or Other Jurisdiction of Incor

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 18, 2023 Arbutus Biopharma

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 18, 2023 Arbutus Biopharma Corporation (Exact name of registrant as specified in its charter) British Columbia, Canada 001-34949 98-0597776 (State or Other Jurisdiction of Incor

Arbutus to Present AB-729 and AB-161 Data at the Global Hepatitis Summit 2023 Two oral presentations scheduled for Thursday, April 27, 2023

EXHIBIT 99.1 Arbutus to Present AB-729 and AB-161 Data at the Global Hepatitis Summit 2023 Two oral presentations scheduled for Thursday, April 27, 2023 WARMINSTER, Pa., April 18, 2023 (GLOBE NEWSWIRE) - Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop novel therapeutics that target specific viral diseas

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant  ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy Stat

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant  ☐ Check the appropriate box:  ☐ Preliminary Proxy Statement  ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ D

Arbutus Biopharma and Genevant Sciences File Patent Infringement Lawsuit Against Pfizer/BioNTech Companies seek compensation for Pfizer’s and BioNTech’s unlicensed use of patented technologies in COVID-19 mRNA-LNP vaccines

EXHIBIT 99.1 Arbutus Biopharma and Genevant Sciences File Patent Infringement Lawsuit Against Pfizer/BioNTech Companies seek compensation for Pfizer’s and BioNTech’s unlicensed use of patented technologies in COVID-19 mRNA-LNP vaccines WARMINSTER, Pa., April 04, 2023 (GLOBE NEWSWIRE) - Arbutus Biopharma Corporation (Nasdaq: ABUS) (“Arbutus”), a clinical-stage biopharmaceutical company leveraging i

Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 4, 2023 Arbutus Biopharma Corporation (Exact name of registrant as specified in its charter) British Columbia, Canada 001-34949 98-0597776 (State or Other Jurisdiction of Incorp

Arbutus Doses First Subject in Phase 1 Clinical Trial with its Oral RNA Destabilizer, AB-161 Initial data expected in the second half of 2023

EXHIBIT 99.1 Arbutus Doses First Subject in Phase 1 Clinical Trial with its Oral RNA Destabilizer, AB-161 Initial data expected in the second half of 2023 WARMINSTER, Pa., March 16, 2023 (GLOBE NEWSWIRE) - Arbutus Biopharma Corporation (Nasdaq: ABUS) (“Arbutus”), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop novel therapeutics that target specifi

Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 16, 2023 Arbutus Biopharma Corporation (Exact name of registrant as specified in its charter) British Columbia, Canada 001-34949 98-0597776 (State or Other Jurisdiction of Incor

Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 14, 2023 Arbutus Biopharma Corporation (Exact name of registrant as specified in its charter) British Columbia, Canada 001-34949 98-0597776 (State or Other Jurisdiction of Incor

Arbutus Presents AB-343 Data at the 36th International Conference on Antiviral Research Antiviral potency, selectivity and favorable PK support further development of AB-343 as potential ritonavir-free oral treatment for COVID-19 and other human coro

EXHIBIT 99.1 Arbutus Presents AB-343 Data at the 36th International Conference on Antiviral Research Antiviral potency, selectivity and favorable PK support further development of AB-343 as potential ritonavir-free oral treatment for COVID-19 and other human coronaviruses WARMINSTER, Pa., March 14, 2023 (GLOBE NEWSWIRE) - Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceut

Description of Securities Registered Pursuant to Section 12 of the Securities Exchange Act of 1934.

Exhibit 4.1 DESCRIPTION OF THE REGISTRANT’S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 As of the date of the Annual Report on Form 10-K of which this exhibit forms a part, the only class of securities of Arbutus Biopharma Corporation (“we,” “us” and “our”) registered under Section 12 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), i

Form of Arbutus Biopharma Corporation Restricted Stock Unit Agreement. (incorporated herein by reference to Exhibit 10.41 of the Registrant’s Annual Report on Form 10-K for the year end December 31, 2022, filed with the SEC on March 2, 2023).

Exhibit 10.41 ARBUTUS BIOPHARMA CORPORATION 2016 OMNIBUS SHARE AND INCENTIVE PLAN RESTRICTED STOCK UNIT AGREEMENT COVER SHEET Arbutus Biopharma Corporation, a corporation incorporated under the laws of British Columbia, Canada (the “Company”), hereby grants Restricted Stock Units (the “RSUs”) representing the right to receive common shares, without par value, of the Company (the “Shares”), to the

Financial Statements and Exhibits, Results of Operations and Financial Condition, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 2, 2023 Arbutus Biopharma Corporation (Exact name of registrant as specified in its charter) British Columbia, Canada 001-34949 98-0597776 (State or Other Jurisdiction of Incorp

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended December 31, 2022 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period from to Commission File Number: 001-34949 Arbutus Biopharma Corpora

NASDAQ: ABUS www.arbutusbio.com March 2, 2023 Corporate Presentation © 2023 Arbutus Biopharma, Inc. Forward - Looking Statements This presentation contains forward - looking statements within the meaning of the U . S . Private Securities Litigation R

EXHIBIT 99.2 NASDAQ: ABUS www.arbutusbio.com March 2, 2023 Corporate Presentation © 2023 Arbutus Biopharma, Inc. Forward - Looking Statements This presentation contains forward - looking statements within the meaning of the U . S . Private Securities Litigation Reform Act of 1995 and Canadian securities laws . All statements that are not historical facts are hereby identified as forward - looking

Arbutus Reports Fourth Quarter and Year End 2022 Financial Results and Corporate Update Significant progress made advancing proprietary programs in chronic HBV and Coronavirus AB-729 data from multiple Phase 2a combination clinical trials expected in

EXHIBIT 99.1 Arbutus Reports Fourth Quarter and Year End 2022 Financial Results and Corporate Update Significant progress made advancing proprietary programs in chronic HBV and Coronavirus AB-729 data from multiple Phase 2a combination clinical trials expected in 2023 Initial Phase 1 data for oral PD-L1, AB-101, and oral RNA Destabilizer, AB-161, expected in the second half of 2023 Initiate Phase

List of Subsidiaries.

Exhibit 21.1 Arbutus Biopharma Corporation List of Subsidiaries Name Jurisdiction Arbutus Biopharma Inc. Delaware, United States of America

ABUS / Arbutus Biopharma Corp / BlackRock Inc. Passive Investment

SC 13G 1 ca03879j1003020323.txt ca03879j1003020323.txt SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No: ) Arbutus Biopharma Corp - (Name of Issuer) Common Stock - (Title of Class of Securities) BZ0QMB7 - (SEDOL Number) December 31, 2022 - (Date of Event Which Requires Filing of this Statement) Check the appropriate box

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 23, 2023 Arbutus Biopharma Corporation (Exact name of registrant as specified in its charter) British Columbia, Canada 001-34949 98-0597776 (State or Other Jurisdiction of Inc

Arbutus Announces Resignation of Board Member

EXHIBIT 99.1 Arbutus Announces Resignation of Board Member WARMINSTER, Pa., Jan. 27, 2023 (GLOBE NEWSWIRE) - Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop novel therapeutics that target specific viral diseases, today announced that Tram Tran, MD has notified the Company of her intention to resign from

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 5, 2023 Arbutus Biopharma

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 5, 2023 Arbutus Biopharma Corporation (Exact name of registrant as specified in its charter) British Columbia, Canada 001-34949 98-0597776 (State or Other Jurisdiction of Inco

NASDAQ: ABUS www.arbutusbio.com January 5, 2023 Corporate Presentation © 2023 Arbutus Biopharma, Inc. Forward - Looking Statements This presentation contains forward - looking statements within the meaning of the U . S . Private Securities Litigation

EXHIBIT 99.2 NASDAQ: ABUS www.arbutusbio.com January 5, 2023 Corporate Presentation ? 2023 Arbutus Biopharma, Inc. Forward - Looking Statements This presentation contains forward - looking statements within the meaning of the U . S . Private Securities Litigation Reform Act of 1995 and Canadian securities laws . All statements that are not historical facts are hereby identified as forward - lookin

Arbutus Announces 2023 Corporate Objectives and Provides Financial Update Data from multiple Phase 2a clinical trials combining AB-729 with other compounds expected in 2023 Plans to advance HBV assets, AB-101 and AB-161, and newly nominated coronavir

EXHIBIT 99.1 Arbutus Announces 2023 Corporate Objectives and Provides Financial Update Data from multiple Phase 2a clinical trials combining AB-729 with other compounds expected in 2023 Plans to advance HBV assets, AB-101 and AB-161, and newly nominated coronavirus asset, AB-343, into Phase 1 clinical trials in 2023 Strong financial position; cash runway into Q4 2024 WARMINSTER, Pa., Jan. 05, 2023

Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 13, 2022 Arbutus Biopharma Corporation (Exact name of registrant as specified in its charter) British Columbia, Canada 001-34949 98-0597776 (State or Other Jurisdiction of In

Arbutus Completes Enrollment in its Phase 2a Clinical Trial Combining AB-729 with NA Therapy and Peginterferon alfa-2a in Patients with Chronic Hepatitis B Virus Infection Preliminary data from lead-in phase further validates AB-729’s capacity to red

EX-99.1 2 exh991.htm PRESS RELEASE EXHIBIT 99.1 Arbutus Completes Enrollment in its Phase 2a Clinical Trial Combining AB-729 with NA Therapy and Peginterferon alfa-2a in Patients with Chronic Hepatitis B Virus Infection Preliminary data from lead-in phase further validates AB-729’s capacity to reduce HBsAg Initial data from IFN phase expected in the first half of 2023 WARMINSTER, Pa., Dec. 13, 202

NASDAQ: ABUS www.arbutusbio.com November 9, 2022 Corporate Presentation Forward - Looking Statements This presentation contains forward - looking statements within the meaning of the U . S . Private Securities Litigation Reform Act of 1995 and Canadi

EXHIBIT 99.2 NASDAQ: ABUS www.arbutusbio.com November 9, 2022 Corporate Presentation Forward - Looking Statements This presentation contains forward - looking statements within the meaning of the U . S . Private Securities Litigation Reform Act of 1995 and Canadian securities laws . All statements that are not historical facts are hereby identified as forward - looking statements for this purpose

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period from to Commission File Number: 001-34949 ARBUTUS BIOPHARM

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 9, 2022 Arbutus Biopharm

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 9, 2022 Arbutus Biopharma Corporation (Exact name of registrant as specified in its charter) British Columbia, Canada 001-34949 98-0597776 (State or Other Jurisdiction of Inc

Arbutus Reports Third Quarter 2022 Financial Results and Provides Corporate Update Financially strong with a projected cash runway into the second quarter of 2024 HBsAg and HBV DNA remain at low levels with no evidence of clinical relapse up to 44 we

EXHIBIT 99.1 Arbutus Reports Third Quarter 2022 Financial Results and Provides Corporate Update Financially strong with a projected cash runway into the second quarter of 2024 HBsAg and HBV DNA remain at low levels with no evidence of clinical relapse up to 44 weeks after discontinuing AB-729, our RNAi therapeutic, and NA therapy On-track to achieve multiple additional milestones before year end C

NASDAQ: ABUS www.arbutusbio.com November 4, 2022 AASLD Data Presentation Forward - Looking Statements This presentation contains forward - looking statements within the meaning of the U . S . Private Securities Litigation Reform Act of 1995 and Canad

Exhibit 99.1 NASDAQ: ABUS www.arbutusbio.com November 4, 2022 AASLD Data Presentation Forward - Looking Statements This presentation contains forward - looking statements within the meaning of the U . S . Private Securities Litigation Reform Act of 1995 and Canadian securities laws . All statements that are not historical facts are hereby identified as forward - looking statements for this purpose

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 4, 2022 Arbutus Biopharm

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 4, 2022 Arbutus Biopharma Corporation (Exact name of registrant as specified in charter) British Columbia, Canada 001-34949 98-0597776 (State or other jurisdiction of incorpo

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 1, 2022 Arbutus Biopharm

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 1, 2022 Arbutus Biopharma Corporation (Exact name of registrant as specified in its charter) British Columbia, Canada 001-34949 98-0597776 (State or Other Jurisdiction of Inc

Arbutus Presents AB-729 Clinical Data and AB-101 Preclinical Data at AASLD - The Liver Meeting® HBsAg and HBV DNA remain at low levels with no evidence of clinical relapse up to 44 weeks after discontinuing AB-729 and NA therapy Preclinical data sugg

EXHIBIT 99.1 Arbutus Presents AB-729 Clinical Data and AB-101 Preclinical Data at AASLD - The Liver Meeting® HBsAg and HBV DNA remain at low levels with no evidence of clinical relapse up to 44 weeks after discontinuing AB-729 and NA therapy Preclinical data suggest that AB-101, an oral PD-L1 inhibitor, in combination with an RNAi, may provide enhanced HBV immune response Data to be presented as p

Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 31, 2022 Arbutus Biopharma Corporation (Exact name of registrant as specified in its charter) British Columbia, Canada 001-34949 98-0597776 (State or Other Jurisdiction of Inc

Arbutus Announces Three Poster Presentations with Clinical Data from AB-729 and Preclinical Data from AB-101 at AASLD - The Liver Meeting® 2022 Conference Call and Webcast to discuss the new data being presented at AASLD scheduled for 8:45 AM ET, Fri

EXHIBIT 99.1 Arbutus Announces Three Poster Presentations with Clinical Data from AB-729 and Preclinical Data from AB-101 at AASLD - The Liver Meeting? 2022 Conference Call and Webcast to discuss the new data being presented at AASLD scheduled for 8:45 AM ET, Friday, November 4, 2022 WARMINSTER, Pa., Oct. 31, 2022 (GLOBE NEWSWIRE) - Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage bi

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 18, 2022 Arbutus Biopharm

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 18, 2022 Arbutus Biopharma Corporation (Exact name of registrant as specified in charter) British Columbia, Canada 001-34949 98-0597776 (State or other jurisdiction of incorpo

, 2022, by and between the Company and Michael McElhaugh.

Exhibit 10.1 THIRD AMENDMENT TO EXECUTIVE EMPLOYMENT AGREEMENT This Third Amendment to Executive Employment Agreement (this “Amendment”) is made effective as of November 1, 2022 (the “Effective Date”) by and between Arbutus Biopharma, Inc. (the “Company”), and Michael McElhaugh (the “Executive”) (together the “Parties”). RECITALS A. The Company and the Executive have entered into an Executive Empl

Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 30, 2022 Arbutus Biopharma Corporation (Exact name of registrant as specified in its charter) British Columbia, Canada 001-34949 98-0597776 (State or Other Jurisdiction of I

Gaston Picchio, PhD, Chief Development Officer, to Depart Arbutus at Year End

EXHIBIT 99.1 Gaston Picchio, PhD, Chief Development Officer, to Depart Arbutus at Year End WARMINSTER, Pa., Sept. 30, 2022 (GLOBE NEWSWIRE) - Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop novel therapeutics that target specific viral diseases, today announced that Gaston Picchio, PhD, Chief Developmen

Arbutus Biopharma Announces Issuance of a New Key U.S. Patent Related to AB-729

EXHIBIT 99.1 Arbutus Biopharma Announces Issuance of a New Key U.S. Patent Related to AB-729 WARMINSTER, Pa., Aug. 30, 2022 (GLOBE NEWSWIRE) - Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop novel therapeutics that target specific viral diseases, today announced that the United States Patent and Tradema

Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 30, 2022 Arbutus Biopharma Corporation (Exact name of registrant as specified in its charter) British Columbia, Canada 001-34949 98-0597776 (State or Other Jurisdiction of Inco

As filed with the Securities and Exchange Commission on August 4, 2022

As filed with the Securities and Exchange Commission on August 4, 2022 Registration No.

Filing Fee Table

EX-FILING FEES 2 a2022s-8feetableex107.htm EX-FILING FEES Exhibit 107 Calculation of Filing Fee Table Form S-8 (Form Type) Arbutus Biopharma Corporation (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered(1) Proposed Maximum Offering Price Per Unit Proposed Maximum Aggregate Offering P

Arbutus Reports Second Quarter 2022 Financial Results and Provides Corporate Update Key milestones across our chronic hepatitis B virus (cHBV) and pan-coronavirus programs remain on track Financially strong with a projected cash runway into the secon

EXHIBIT 99.1 Arbutus Reports Second Quarter 2022 Financial Results and Provides Corporate Update Key milestones across our chronic hepatitis B virus (cHBV) and pan-coronavirus programs remain on track Financially strong with a projected cash runway into the second quarter of 2024 Conference Call and Webcast Today at 8:45 AM ET WARMINSTER, Pa., Aug. 04, 2022 (GLOBE NEWSWIRE) - Arbutus Biopharma Cor

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period from to Commission File Number: 001-34949 ARBUTUS BIOPHARMA COR

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 4, 2022 Arbutus Biopharma Corporation (Exact name of registrant as specified in its charter) British Columbia, Canada 001-34949 98-0597776 (State or Other Jurisdiction of Incor